---
title: "AMRX: Q2 revenue and profit surged, outlook raised, and biosimilar expansion accelerates with Kashiv"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294381748.md"
description: "Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The pending Kashiv acquisition will create a fully integrated biosimilar platform, while guidance for 2026 was raised across all key metrics.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T14:21:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294381748.md)
  - [en](https://longbridge.com/en/news/294381748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294381748.md)
generator: "portal-rs"
---

# AMRX: Q2 revenue and profit surged, outlook raised, and biosimilar expansion accelerates with Kashiv

Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The pending Kashiv acquisition will create a fully integrated biosimilar platform, while guidance for 2026 was raised across all key metrics.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [AMRX.US](https://longbridge.com/en/quote/AMRX.US.md)

## Related News & Research

- [CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session](https://longbridge.com/en/news/298589195.md)
- [Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss](https://longbridge.com/en/news/298988404.md)
- [DERM: EMROSI's rapid market adoption and clinical superiority are fueling significant growth in dermatology](https://longbridge.com/en/news/298938598.md)
- [Intelligent Bio Solutions submits FDA 510(k) filing for fingerprint drug test system seeking codeine clearance](https://longbridge.com/en/news/298458663.md)
- [WST: Raised guidance and margin expansion reflect strong HVP-driven growth and strategic investments](https://longbridge.com/en/news/298609990.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**